Analysts Expect BioDelivery Sciences International, Inc. (BDSI) Will Post Quarterly Sales of $8.89 Million

Equities analysts expect BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to report sales of $8.89 million for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for BioDelivery Sciences International’s earnings. The lowest sales estimate is $8.37 million and the highest is $9.52 million. BioDelivery Sciences International posted sales of $3.57 million during the same quarter last year, which suggests a positive year-over-year growth rate of 149%. The firm is expected to report its next quarterly earnings results on Wednesday, November 8th.

According to Zacks, analysts expect that BioDelivery Sciences International will report full year sales of $8.89 million for the current year, with estimates ranging from $55.36 million to $64.10 million. For the next financial year, analysts forecast that the company will post sales of $49.46 million per share, with estimates ranging from $44.33 million to $55.40 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover BioDelivery Sciences International.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.04). BioDelivery Sciences International had a net margin of 3.34% and a return on equity of 14.64%. The business had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.45 million. During the same period last year, the firm posted ($0.31) earnings per share. The company’s quarterly revenue was up 74.0% on a year-over-year basis.

A number of equities analysts have recently issued reports on BDSI shares. Janney Montgomery Scott increased their price objective on shares of BioDelivery Sciences International from $3.00 to $4.00 and gave the company a “fair value” rating in a research note on Monday, July 24th. HC Wainwright started coverage on shares of BioDelivery Sciences International in a research note on Sunday, September 10th. They issued a “buy” rating and a $5.00 price objective for the company. Zacks Investment Research cut shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research note on Monday, July 17th. ValuEngine cut shares of BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of BioDelivery Sciences International in a research note on Sunday, August 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $4.29.

TRADEMARK VIOLATION NOTICE: This news story was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/2956135/analysts-expect-biodelivery-sciences-international-inc-bdsi-will-post-quarterly-sales-of-8-89-million.html.

In related news, CEO Mark A. Sirgo sold 65,405 shares of the stock in a transaction dated Wednesday, September 20th. The shares were sold at an average price of $2.75, for a total transaction of $179,863.75. Following the completion of the sale, the chief executive officer now owns 1,509,262 shares in the company, valued at approximately $4,150,470.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mark A. Sirgo sold 201,373 shares of the stock in a transaction dated Thursday, September 21st. The stock was sold at an average price of $2.84, for a total transaction of $571,899.32. Following the sale, the insider now owns 1,509,262 shares of the company’s stock, valued at approximately $4,286,304.08. The disclosure for this sale can be found here. Insiders have sold a total of 402,127 shares of company stock valued at $1,142,798 in the last quarter. 9.00% of the stock is currently owned by corporate insiders.

Several institutional investors have recently made changes to their positions in BDSI. Valley National Advisers Inc. increased its position in shares of BioDelivery Sciences International by 59.0% during the 2nd quarter. Valley National Advisers Inc. now owns 37,715 shares of the specialty pharmaceutical company’s stock worth $106,000 after purchasing an additional 14,000 shares in the last quarter. Cutter & CO Brokerage Inc. increased its position in shares of BioDelivery Sciences International by 2.4% during the 2nd quarter. Cutter & CO Brokerage Inc. now owns 43,430 shares of the specialty pharmaceutical company’s stock worth $122,000 after purchasing an additional 1,000 shares in the last quarter. Advisor Group Inc. increased its position in shares of BioDelivery Sciences International by 42.1% during the 2nd quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock worth $126,000 after purchasing an additional 13,341 shares in the last quarter. NEXT Financial Group Inc increased its position in shares of BioDelivery Sciences International by 9.3% during the 2nd quarter. NEXT Financial Group Inc now owns 47,000 shares of the specialty pharmaceutical company’s stock worth $132,000 after purchasing an additional 4,000 shares in the last quarter. Finally, Sterling Investment Management Inc. acquired a new stake in shares of BioDelivery Sciences International during the 2nd quarter worth about $140,000. Institutional investors and hedge funds own 41.43% of the company’s stock.

BioDelivery Sciences International (NASDAQ BDSI) traded down 0.847% on Monday, hitting $2.925. 1,199,021 shares of the stock traded hands. BioDelivery Sciences International has a 12-month low of $1.50 and a 12-month high of $3.60. The stock has a 50-day moving average of $2.95 and a 200-day moving average of $2.58. The firm has a market cap of $162.26 million, a price-to-earnings ratio of 104.464 and a beta of 0.95.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.